MedTrace Logo

Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy

NCT00160966 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2017-03-28

No results posted yet for this study

Summary

The aim of this study is to characterize and evaluate risk factors of polyomavirus nephropathy (PVN) including the impact of three immunosuppressive regimens.

Conditions

  • Polyomavirus Infections

Interventions

DRUG

Ciclosporin and Mycophenolate-mofetil

according to the Giessen protocol

DRUG

Tacrolimus and Mycophenolate-mofetil

according to Giessen protocol

DRUG

Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus

according to Giessen protocol

Sponsors & Collaborators

  • Heidelberg University

    collaborator OTHER

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • University of Giessen

    lead OTHER

Principal Investigators

  • Rolf Weimer, Prof., MD · University Giessen, Internal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160966 on ClinicalTrials.gov